ArticleThe Pan African medical journal2026
Ocular mpox in Southern Nigeria during the 2022 and 2024 outbreaks: a report of two cases.
Article in The Pan African medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are significant knowledge gaps regarding the burden and clinical progression of ocular manifestations of mpox in Nigeria and worldwide. Here, we report two laboratory-confirmed mpox cases among young male adults with distinct ocular mpox presentations at two tertiary hospitals in southern Nigeria during the 2022 and 2024 global outbreaks. The first patient, a 28-year-old man, presented at the Alex Ekwueme Federal University Teaching Hospital in Abakaliki with a vesiculopustular rash on his nasal bridge and right lower eyelid, along with redness, pain, and itching. He subsequently developed corneal ulcers and vision problems after discharge, necessitating an ophthalmology review. The second case involved a 44-year-old man with advanced HIV, who presented with widespread vesiculo-pustular eruptions, including characteristic periorbital and orbital rashes. He presented with widespread vesiculo-pustular skin eruptions, including characteristic rashes around the periorbital and orbital areas. His condition deteriorated rapidly, leading to his death after seven days of hospitalisation. Consistent with guidance from the Nigeria Center for Disease Control and Prevention, lesional skin swabs from both patients were sent to the National Reference Laboratory in Abuja for quantitative polymerase chain reaction (qPCR), which tested positive for the monkeypox virus. Supportive care included antibiotics, antivirals, intravenous fluids, nutritional support, and skin care, as no specific mpox treatments were available at that time. Ocular disease has emerged as an increasingly common yet underreported manifestation of mpox in Nigeria since the 2022 global outbreak. Ophthalmologists should be part of the multidisciplinary team of specialists caring for mpox patients with ocular manifestations. Ongoing surveillance and research are vital to better understand eye-related complications and to improve the prevention and treatment of ocular symptoms, thereby preventing significant vision loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.